Fingerprint The fingerprint is based on mining the text of the scientific documents related to the associated persons. Based on that an index of weighted terms is created, which defines the key subjects of research unit

Neoplasms Medicine & Life Sciences
Ovarian Neoplasms Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Doxorubicin Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Adenoma Medicine & Life Sciences
Melanoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1977 2021

Metformin
Obesity
Breast Neoplasms
Adiposity
Weight Gain

Allostery and Cellular Distribution of the Nitric Oxide Recepto, Soluble...

Briehl, M. M., Garcia, F. A., Alberts, D. S., Martinez, J. D., Adams, A., Canfield, L., Garcia, F. A., Gage, M., Weinert, T. A., Stearns, D., Ingram, J. C., Pearson, T. R., Schwartz, A., Solomon, T. G. A., Trujillo, O. & Wilder, J.

National Institutes of Health

9/1/098/31/19

Project: Research projectSpecialized Center--Cooperative Agreements

North American Indians
Neoplasms
Community-Institutional Relations
Research
cancer

Medical University of South Carolina - Cancer Center Support Grant

Kraft, A., Zhou, D., Obeid, L., Bielawska, A., Harrison, A. L., Garrett-Mayer, E., Lemasters, J., Hall, P., Stuart, R. & Alberg, A.

National Institutes of Health

4/1/09 → …

Project: Research projectCenter Core Grants

Neoplasms
Research
cancer
program planning
Biostatistics

Research Output 1975 2018

18F-FDG PET/CT can predict development of thyroiditis due to immunotherapy for lung cancer

Eshghi, N., Garland, L. L., Nia, E., Betancourt, R., Krupinski, E. A. & Kuo, P. H., Sep 1 2018, In : Journal of Nuclear Medicine Technology. 46, 3, p. 260-264 5 p.

Research output: Contribution to journalArticle

Thyroiditis
Fluorodeoxyglucose F18
Immunotherapy
Lung Neoplasms
Hypothyroidism
adenoma
physical activity
Adenoma
odds ratio
Odds Ratio

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

Clark, J. I., Singh, J., Ernstoff, M. S., Lao, C. D., Flaherty, L. E., Logan, T. F., Curti, B., Agarwala, S. S., Taback, B., Cranmer, L. D., Lutzky, J., Luna, T. L., Aung, S. & Lawson, D. H., Jul 27 2018, In : Journal for ImmunoTherapy of Cancer. 6, 1, 76.

Research output: Contribution to journalArticle

Interleukin-2
Melanoma
Mutation
Antigen Presentation
Neoplasm Antigens